
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALLEGRA ALLERGY | Sanofi | N-020872 OTC | 2011-01-24 | 1 products, RLD |
| ALLEGRA HIVES | Sanofi | N-020872 OTC | 2011-01-24 | 1 products, RLD, RS |
| ALLEGRA ALLERGY | Sanofi | N-020872 OTC | 2011-01-24 | 1 products, RLD, RS |
| CHILDREN'S ALLEGRA ALLERGY | Sanofi | N-201373 OTC | 2011-01-24 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| 12hr allergy relief | ANDA | 2021-09-24 |
| 24hr allergy relief | ANDA | 2025-06-12 |
| allegra allergy | New Drug Application | 2025-02-19 |
| allegra allergy 24 hour | C200263 | 2025-02-11 |
| allegra allergy allegra allergy, travel basix | New Drug Application | 2024-11-19 |
| allegra allergy childrens allegra allergy | New Drug Application | 2014-03-24 |
| allegra d 12 hour allergy and congestion | New Drug Application | 2014-03-19 |
| allegra d-12 hour | New Drug Application | 2009-12-08 |
| allegra hives 24hr | New Drug Application | 2024-11-18 |
| allegra--d 24 hour | New Drug Application | 2012-09-25 |
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Fexofenadine Hydrochloride, Children'S Allegra Allergy, Chattem Sanofi | |||
| 8933097 | 2030-08-02 | DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis | D065631 | — | J30.9 | — | 1 | 3 | 9 | — | 12 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | 1 | 3 | 9 | — | 12 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | — | 2 | 2 | — | 4 |
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | 1 | 1 | 1 | — | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | 1 | — | 1 |
| Fabry disease | D000795 | Orphanet_324 | E75.21 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 3 | — | — | 3 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | 1 | — | — | 1 |
| Eczema | D004485 | — | L30.9 | — | 1 | 1 | — | — | 1 |
| Dermatitis | D003872 | — | L30.9 | — | 1 | 1 | — | — | 1 |
| Pruritus | D011537 | — | L29 | — | — | 1 | — | — | 1 |
| Drug common name | Fexofenadine |
| INN | fexofenadine |
| Description | Fexofenadine is a piperidine-based anti-histamine compound. It has a role as a H1-receptor antagonist and an anti-allergic agent. It is a member of piperidines and a tertiary amine. It is functionally related to an isobutyric acid. |
| Classification | Small molecule |
| Drug class | Antihistamine; H1 receptor antagonist |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1 |
| PDB | — |
| CAS-ID | 83799-24-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL914 |
| ChEBI ID | 5050 |
| PubChem CID | 3348 |
| DrugBank | DB00950 |
| UNII ID | E6582LOH6V (ChemIDplus, GSRS) |











